































	 A	 series	 of	 new	 fluoroquinolones	 analogs	 (3a‐i)	 were	 prepared	 under	 conventional	 andmicrowave	 irradiation	 technique.	 Ethyl	 1‐cyclopropyl‐6,7‐difluoro‐8‐methoxy‐4‐oxo‐1,4‐
dihydroquinoline‐3‐carboxylate	 (1)	on	reaction	with	boric	acid	and	acetic	anhydride	 in	the
presence	 of	 catalytic	 amount	 of	 zinc	 chloride	 under	 reflux,	 resulted	 in	 an	 unstable	 borate
complex.	Which	was	 instantaneously	 treated	with	morpholine,	 piperidine,	 thiomorpholine,
2,6‐dimethylmorpholine,	 4,5,6,7‐tetrahydrothieno[3,2‐c]pyridine	 hydrochloride,	 5,6,7,7a‐
tetrahydrothieno[3,2‐c]pyridin‐2(4H)‐one	hydrochloride,	2,3‐dichlorophenylpiperazine
hydrochloride,	 3‐(piperidin‐4‐yl)benzo[d]isoxazole	 hydrochloride	 and	 5,6,7,8‐tetrahydro‐
[1,2,4]	triazolo[4,3‐a]pyrazine,	in	the	presence	of	triethylamine	to	yield	compounds	3a‐i.	The
same	compounds	on	the	other	hand	synthesized	using	a	microwave	irradiation	technique	in
the	 presence	 of	 triethylamine	 and	 adsorbed	 neutral	 alumina.	 The	 structures	 of	 the
synthesized	 compounds	were	 established	 on	 the	 basis	 of	 spectral	 and	 analytical	 data.	 The













Fluoroquinolones	 belong	 to	 broad	 spectrum	 antibiotics,	
therapeutically	 used	 in	 the	 treatment	 of	 variety	 of	 Gram‐
positive	and	Gram‐negative	bacteria	with	minimum	toxic	side‐
effects	 [1,2].	 Fluoroquinolone	 derivatives	 exhibit	 various	
pharmacological	 properties	 such	 as	 antimicrobial	 [3],	 anti‐
inflammatory	[4],	analgesic	[5]	and	antiviral	[6].	The	structure	
activity	 relationship	 (SAR)	 studies	 of	 the	 fluoroquinolone	
pharmacophore	 led	 to	 synthesize	 new	 class	 of	 compounds	
with	 superior	 bactericidal	 activity.	 These	 derivatives	 inhibit	
two	bacterial	enzymes	namely	DNA	gyrase	and	topoisomerase	
IV	 due	 to	 presence	 of	 fluorine	 atom	 at	 6th	 position	 and	
modification	 at	 7th	 position	 fluoroquinolones	 have	 also	 been	
incurporated	 in	 a	 variety	 of	 therapeutically	 interesting	 anti‐
bacterial	 drugs	 such	 as	 ciprofloxacin,	 levofloxacin	 and	moxif‐
loxacin.	On	 the	other	hand,	heterocyclic	 compounds	substitu‐
ted	 with	 various	 compounds	 2a‐i,	 morpholine,	 piperidine,	
thiomorpholine,	 2,	 6‐dimethyl	 morpholine,	 4,5,6‐tetrahydro	
thieno[3,2‐c]pyridine	 hydrochloride,	 5,6,7,7a‐tetra‐hydro	
thieno[3,2‐c]pyridin‐2(4H)‐one	 hydrochloride,	 2,3‐dichloro	
phenyl	 piperazine	 hydrochloride,	 3‐(piperidin‐4‐yl)benzo[d]	
isoxazole	hydrochloride	and	5,6,7,8‐tetrahydro‐[1,2,4]triazolo	
[4,3‐a]pyrazine	are	a	promising	class	of	bioactive	heterocyclic	
compounds,	 exhibit	 a	 wide	 range	 of	 medicinal	 applications.	
These	 include	 anti‐cancer	 [7],	 anti‐microbial	 [8],	 anti‐fungal	
[9]	and	anti‐viral	[10]	activity.	
A	 survey	 of	 the	 literature	 indicates	 that	 chemical	 substi‐
tution	at	C‐7	position	of	 fluoroquinolone	 ring	 system	possess	
improved	 antibacterial	 activities.	 The	 pharmacological	
importance	of	 substituted	 fluoroquinolones	has	motivated	us	
to	 prepare	 a	 class	 of	 new	 fluoroquinolone	 derivatives	 (3a‐i)	
[11‐13].	 Herein,	 we	 reported	 the	 facile	 synthesis	 of	 1‐cyclo	
propyl‐6,7‐difluoro‐8‐methoxy‐4‐oxo‐1,4‐dihydroquinoline‐3‐








































Thin	 layer	 chromatography	 (TLC)	 was	 carried	 out	 on	
aluminium	 sheets	 coated	 with	 silica	 gel	 60F254	 (Merck,	
Darmstadt,	 Germany).	 TLC	 plates	 were	 inspected	 under	 UV	
light.	 Elemental	 analyses	data	were	 obtained	 by	 employing	 a	
Perkin‐Elmer	 240c	 analyser	 (Waltham,	MA).	 IR	 spectra	 (KBr	
pellets)	 were	 recorded	 with	 a	 Perkin‐Elmer	 1700	 spectro‐
photometer	 (Waltham,	 MA).	 1H	 NMR	 and	 13C	 NMR	 spectra	
were	 measured	 on	 BRUKER	 Avance	 300	 MHz	 spectrometer	
(Bruker,	 Bremen,	 Germany).	 Mass	 was	 recorded	 on	 Varian	








hydroquinoline‐3‐carboxylate	 (1)	 (5	 g,	 17.6	 mmol)	 was	
treated	 with	 morpholine,	 piperidine,	 thiomorpholine,	 2,6‐
dimethyl	 morpholine,	 4,5,6,7‐tetrahydrothieno[3,2‐c]pyridine	
hydrochloride,	 5,6,7,7a‐tetrahydrothieno[3,2‐c]pyridin‐2(4H)‐








The	 reaction	 mixture	 was	 cooled	 to	 room	 temperature	 and	
purified	 by	 SiO2	 gel	 column	 chromatography	 with	 9:1	






hydroquinoline‐3‐carboxylate	 (1)	 (100	 g,	 309.31	mmol)	 was	
added	 into	 a	 1.0	 L	 round	 bottom	 flask	 followed	 by	 acetic	
anhydride	 (200	 mL)	 under	 stirring	 and	 the	 contents	 are	
heated	 to	 90‐95	 °C	 for	 2	 hrs	 and	 cooled	 to	 50‐55	 °C.	 At	 this	
temperature,	 boric	 acid	 (27.2	 g,	 439.91	mmol)	was	 added	 in	
three	 lots	with	1	hr	 interval	 for	 each	 lot	 and	 again	heated	 to	





15	 hrs	 until	 constant	 weight	 attained.	 The	 resulted	 borate	
complex	 I	 (5	 g,	 11.08	 mmol)	 immediately	 dissolved	 in	
acetonitrile	 (50	 mL,	 10	 Volumes)	 and	 treated	 with	 different	
substituted	 morpholine,	 piperidine,	 thiomorpholine,	 2,6‐
dimethylmorpholine,	 4,5,6,7‐tetrahydrothieno[3,2‐c]pyridine	
hydrochloride,	 5,6,7,7a‐tetrahydrothieno[3,2‐c]pyridin‐2(4H)‐






monitored	 by	 TLC,	 the	 reaction	 mixture	 was	 poured	 into	
crushed	 ice	 and	 pH	 was	 adjusted	 to	 below	 2.0	 with	 dil.	
hydrochloric	 acid,	 stirred	 for	 1‐2	 hrs	 at	 20‐30	 °C.	 The	
precipitated	 product	 was	 filtered,	 washed	 with	 water	 and	
dried	 to	 obtain	 crude.	 The	 latter	 on	 re	 crystallization	 from	
methanol	gave	pure	compounds	3a‐i	(Scheme	1).	
1‐Cyclopropyl‐6‐fluoro‐8‐methoxy‐7‐morpholino‐4‐oxo‐1,	 4‐







DMSO‐d6,	 δ,	ppm):	1.037	 (m,	2H,	 cyclopropane),	 1.10	 (m,	2H,	




COOH),	 166.3	 (1C,	 C=O),	 148.1	 (1C,	 CH),	 146.3	 (1C,	 C),	 145.6	
(1C,	C),	132.5(1C,	C),	129.7	(1C,	C),	119.2	(1C,	C),	109.3	(1C,	C),	
108.8	 (1C,	 CH),	 66.4	 (2C,	 2×CH2),	 55.9	 (1C,	 OCH3),	 46.6	 (2C,	





1,4‐dihydroquinoline‐3‐carboxylic	 acid	 hydrochloride	 (3b):	
Color:	 Yellow.	 Yield:	 75.7%	 c	 and	 82.3%	 m.	M.p.:	 222‐224	 °C.	
FT‐IR	(KBr,	,	cm‐1):	3449	(OH),	2973	(CH),	2941	(CH)	,	2123	
(CH),	1732	(C=O),	1556	(C=O),	1466	(C=C),	1415	(C=C),	1370	
(C‐N),	 1336	 (‐C=C),	 1298	 (C‐O),	 1237	 (C‐N),	 1187	 (Ar‐C=C),	
1103	(C‐F).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	1.045‐1.027	
(m,	 2H,	 cyclopropane),	 1.150‐1.101	 (m,	 2H,	 cyclopropane),	
1.659	 (m,	 6H,	 3×CH2,	 piperidine),	 3.32	 (m,	 4H,	 2×CH2,	
piperidine),	 3.761	 (s,	 3H,	 OCH3),	 4.189‐4.154	 (m,	 1H,	 cyclo	
propane),	 7.750‐7.720	 (s,	 J	 =	 9	 Hz,	 1H,	 Ar‐H),	 8.696	 (s,	 1H,	
Olefinic	 proton),	 15.001	 (s,	 1H,	 COOH).	 13C	 NMR	 (75	 MHz,	
DMSO‐d6,	δ,	ppm):	177.5	(1C,	C=O),	166.3	(1C,	C=O),	148.1	(1C,	
CH),	146.3	(1C,	C),	145.6	 (1C,	C),	132.5	(1C,	C),	129.7	(1C,	C),	
119.2	 (1C,	 C),	 109.3	 (1C,	 C),	 108.8	 (1C,	 CH),	 55.9	 (1C,	OCH3),	
52.7	 (2C,	 2×CH2),	 36.3	 (1C,	 CH),	 25.9	 (1C,	 CH2),	 25.5	 (2C,	




1,4‐dihydroquinoline‐3‐carboxylic	 acid	 hydrochloride	 (3c):	




DMSO‐d6,	 δ,	 ppm):	 1.037	 (m,	2H,	 cyclopropane),	 1.10	 (m,	 2H,	
cyclopropane),	3.329	(m,	4H,	2×CH2),	3.62	(m,	4H,	2×CH2),	3.81	
(s,	3H,	OCH3),	4.45‐4.44	(m,	1H,	cyclopropane),	7.789‐7.792	(d,	
J	 =	9.3	Hz,	1H,	Ar‐H),	9.08	 (s,	 1H,	Olefinic	proton),	 14.931	 (s,	
1H,	 COOH).	 13C	 NMR	 (75	MHz,	 DMSO‐d6,	 δ,	 ppm):	 177.5	 (1C,	
COOH),	 166.3	 (1C,	 C=O),	 148.1	 (1C,	 CH),	 146.3	 (1C,	 C),	 145.6	
(1C,	CH),	132.5	(1C,	CH),	129.7	(1C,	CH),	119.2	(1C,	CH),	109.3	
(1C,	C),	108.8	(1C,	CH),	66.4	(2C,	2×CH2),	55.9	(1C,	OCH3),	46.6	





ride	 (3d):	 Color:	Off	white.	 Yield:	 63.2%	 c	 and	 92.1%	m.	M.p.:	
202‐213	°C.	FT‐IR	(KBr,	,	cm‐1):	3345	(OH),	2725	(CH),	2562	
(‐C‐H),	1745	(C=O),	1715	(C=O),	1492	(C=C),	1362	(C‐F),	792	
(=C‐H).	 1H	 NMR	 (300	MHz,	 DMSO‐d6,	 δ,	 ppm):	 1.14‐0.86	 (m,	
4H,	 cyclopropane),	 1.21	 (m,	 6H,	 2×CH3),	 1.36	 (m,	 1H,	
cyclopropane),	2.7	(m,	2H,	CH2),	3.10	(m,	2H,	CH2),	3.702‐3.60	
(s,	3H,	OCH3),	3.84	(m,	2H,	CH),	7.95‐7.953	(d,	 J	=	9.3	Hz,	1H,	




(2C,	2×CH),	 66.4	 (2C,	 2×CH2),	 55.9	 (1C,	OCH3),	 36.3	 (1C,	 CH),	
20.5	 (2C,	 2×CH3),	 5.6	 (2C,	 2×CH2).	 Anal.	 calcd.	 for	




acid	 hydrochloride	 (3e):	 Color:	 Off	 white.	 Yield:	 75.4%	 c	 and	
90.1%	 m.	 M.p.:	 202‐204	 °C.	 FT‐IR	 (KBr,	 ,	 cm‐1):	 3395	 (OH),	
2974	 (CH),	 2940	 (CH),	 1731	 (C=O),	 1464	 (C=O),	 1415	 (C=C),	
1331	 (C=C),	 1251	 (Ar‐C=C),	 1215	 (C‐F).	 1H	 NMR	 (300	 MHz,	
DMSO‐d6,	 δ,	 ppm):	 1.074	 (m,	 4H,	 cyclopropane),	 3.075‐3.007	





148.1	 (1C,	 CH	 ),	 146.3	 (1C,	 C),	 145.6	 (1C,	 CH),	 141.6	 (1C,	 C),	
135.2	 (1C,	C),	132.5	 (1C,	CH),	129.7	 (1C,	CH),	119.2	 (1C,	CH),	
109.3	(1C,	C),	108.8	(1C,	CH),	62.3	(1C,	CH2),	55.9	(1C,	OCH3),	










F).	 1H	 NMR	 (300	 MHz,	 DMSO‐d6,δ,	 ppm):	 1.074	 (m,	 4H,	






CH),	141.6	 (1C,	C),	132.5	 (1C,	CH),	129.7	 (1C,	CH),	119.2	 (1C,	
CH),	 109.3	 (1C,	 C),	 108.8	 (1C,	 CH),	 62.3	 (1C,	 CH2),	 55.9	 (1C,	
OCH3),	 55.6	 (1C,	 CH2),	 55.1	 (1C,	CH),	36.3	 (1C,	 CH),	24.5	 (1C,	









1H	 NMR	 (300	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 1.045	 (m,	 2H,	




14.99	 (s,	 1H,	 COOH).	 13C	 NMR	 (75	 MHz,	 DMSO‐d6,	 δ,	 ppm):	
177.5	 (1C,	 C=O),	 166.3	 (1C,	 C=O),	 152.1	 (1C,	 CH),	 148.1	 (1C,	
CH),	146.3	 (1C,	C),	145.6	 (1C,	CH),	134.3	 (1C,	CH),	132.5	 (1C,	
CH),	129.7	 (1C,	C),	129.2	 (1C,	CH),	123.8	 (1C,	CH),	119.8	 (1C,	
CH),	119.2	 (1C,	CH),	113.8	 (1C,	CH),	109.3	 (1C,	C),	108.8	 (1C,	
CH),	55.9	(1C,	OCH3),	49.9	(2C,	2×CH2),	49.1	(2C,	2×CH2),	36.3	





hydrochloride	 (3h):	 Color:	 Pale	 yellow.	 Yield:	 80.7%	 c	 and	
83.9%	 m.	 M.p.:	 226‐228	 °C.	 FT‐IR	 (KBr,	 ,	 cm‐1):	 3386	 (OH),	
2980	 (CH),	 2129	 (CH),	 1547	 (C=O),	 1466	 (C=O),	 1415	 (C=C),	
1372	(C=C),	1299	(Ar‐C=C),	1123	(C‐F),	1078	(C‐O),	1009	(=C‐
H).	 1H	 NMR	 (300	MHz,	 DMSO‐d6,	 δ,	 ppm):	 1.15‐1.05	 (m,	 4H,	
cyclopropane),	1.23	(m,	2H,	CH2),	2.04‐2.01	(m,	2H,	CH2),	2.18	
(m,	2H,	CH2),	2.78	(m,	1H,	CH),	3.61	(m,	2H,	CH2),	3.82	(s,	3H,	
OCH3),	 4.20	 (m,	 1H,	 cyclopropane),	 7.36‐7.33	 (m,	 2H,	 Ar‐H),	
7.80‐7.72	 (m,	 2H,	 Ar‐H),	 8.08	 (m,	 1H,	 Ar‐H),	 8.72	 (s,	 1H,	
























3a	 48.57	 33.33	 28.00 26 30 29 14.66	
3b	 29.52	 26.66	 20.33 18 28 21 ‐	
3c	 31.66	 17.33	 23.57	 19	 30	 20	 ‐	
3d	 32.66	 22.52	 18.66	 19	 28	 22	 20.33	
3e	 34.57	 23.52	 20.33	 20	 23	 20	 10.66	
3f	 18.57	 18.33	 16.57 17 24 15 9.33	
3g	 32.66	 20.66	 14.66 29 20 15 ‐	
3h	 33.57	 19.33	 18.57 13 20 15 21.33	
3i	 43.57	 32.33	 26.66 29 36 26 29.57	
Standard	 24.11	 28.66	 31.57	 21.2	 21	 22	 40	
	
	
CH),	 119.2	 (1C,	 C),	 117.8	 (1C,	 C),	 110.0	 (1C,	 CH),	 109.3	 (1C,	
CH),	108.8	 (1C,	CH),	96.9	 (1C,	CH),	55.9	 (1C,	OCH3),	50.1	 (2C,	
2xCH2),	36.3	(1C,	CH),	35.4	(1C,	CH),	29.8	(2C,	2xCH2),	5.6	(2C,	
2×CH2).	 Anal.	 calcd.	 for	 C26H25ClFN3O5:	 C,	 60.76;	 H,	 4.90;	 N,	




3‐carboxylic	 acid	 (3i):	 Color:	 Off	 white.	 Yield:	 55.4%	 c	 and	
83.1%	 m.	 M.p.:	 195‐226	 °C.	 FT‐IR	 (KBr,	 ,	 cm‐1):	 3375	 (OH),	






MHz,	 DMSO‐d6,	 δ,	 ppm):	 177.8	 (1C,	 C=O),	 166.3	 (1C,	 C=O),	
163.7	(1C,	C),	148.3	(1C,	CH),	146.6	(1C,	C),	145.6	(1C,	C),	141.6	
(1C,	CH),	132.5	(1C,	C),	129.7	(1C,	C),	119.7	(1C,	CH),	109.3	(1C,	








their	 anti‐bacterial	 activity	 against	 three	 Gram	 positive	
organisms	 namely	 Bacillus	 megaterium	 (MTCC	 1936),	
Staphylococcus	 aureus	 (MTCC	 1936)	 and	 Streptococcus	
pyogenes	(MTCC	1936)	procured	from	Microbial	Type	Culture	
Collection	 Institute	 of	 Microbial	 Technology,	 Chandigarh	
(MTCC).	 The	 lyophilised	 culture	was	 activated	by	 inoculating	
into	TSA	+	5%	defibrinated	sheep	blood	and	incubated	at	37	°C	
for	 48	 hrs.	 This	 culture	 was	 taken	 further	 to	 follow	 the	
procedure	 of	 MIC	 and	 antimicrobial	 sensitivity.	 Growth	
medium	 for	 testing	 sensitivity	 used	 nutrient	 agar	 media,	
peptone:	 5	 g,	 beef	 extract:	 3	 g,	 sodium	 chloride	 (NaCl):	 5	 g,	
agar:	 20	 g	 (pH	 =	 7)	 and	 distilled	 water:	 1000	 mL	 used	 for	
testing	sensitivity	of	the	compounds.	
The	 in‐vitro	 antibacterial	 assays	 were	 carried	 out	 by	
adopting	 the	 Kirby	 Bauer	 method	 according	 to	 the	 National	
Committee	 for	 Clinical	 Laboratory	 Standards	 procedures	 for	
aerobic	 testing	 [14].	 The	 microbe	 tested	 was	 sub‐cultured	
twice	 on	 Mueller‐Hinton	 agar,	 and	 the	 colonies	 (5‐7)	 were	
then	 transferred	 aseptically	 into	 individual	 tubes	 containing	
sterile	nutrient	broth	(10	mL).	The	tubes	were	incubated	for	a	
period	 of	 8‐12	 hrs	 at	 37	 °C	 to	 attain	 growth	 at	 log	 phase.	
Subsequently,	 these	 inoculates	 were	 diluted	 with	 sterile	
distilled	 water	 to	 obtain	 a	 density	 corresponding	 approxi‐
mately	 to	 0.5	 McFarland	 standard	 turbidity	 scale	 (1×106	
CFU/mL).	 100	 µL	 of	 the	 test	 organism	 is	 aseptically	 trans‐
ferred	to	the	sterile	nutrient	agar	plates	(each	plate	containing	
20‐25	 mL	 of	 the	 sterile	 agar	 medium)	 and	 spread	 plate	
technique	was	followed	using	a	sterile	L‐shaped	glass	rod.	The	
organisms	were	 allowed	 to	 settle	 on	 the	medium	 for	5	mins.	
Using	a	sterile	cork	borer	6mm	bore	was	done.	100	µL	of	the	
test	 sample	 was	 transferred	 aseptically	 into	 the	 bore.	 In	 the	
same	 plate	 standard	 (Cefixime	 1	mg/mL)	 as	 positive	 control	





Pseudomonas	aeruginosa	 (MTCC	779),	Escherichia	 coli	 (MTCC	
443)	and	Klebsiella	pneumoniae	 (MTCC	530)	were	 inoculated	
into	25	mL	Luria	Bertini	(LB)	broth	and	incubated	in	a	shaker	
at	 37	 °C	 and	 150	 rpm	 overnight	 (Table	 1).	 The	 synthesized	
compounds	3a‐i	considered	for	the	study	was	dissolved	DMSO	
in	aliquots	400	µg	concentrations.	These	concentrations	were	




mL	 agar	 into	 sterile	 petri	 plates	 in	 the	 laminar	 chamber	 and	
allow	to	solidify.	100	μL	of	the	cultures	were	spread	onto	each	
plate	 using	 a	 spreader.	 5	 wells	 were	 punched	 on	 each	 plate	
using	8mm	mega	bore	for	five	different	sample	concentrations.	
100	 μL	 of	 each	 sample	 were	 loaded	 into	 the	 wells	 and	 the	
plates	 were	 incubated	 at	 37	 °C	 for	 17	 hrs.	 The	 zone	 of	
inhibition	was	 observed	 and	 antifungal	 activity	 to	 determine	
the	sensitivity	of	the	given	newly	synthesized	samples	against	
the	selected	fungal	species	Cladosporium	sps	(MTCC),	by	using	
the	 CLSI	 has	 proposed	 a	 diffusion	 method	 for	 mold	 suscep‐




from	 0.9	 to	 0.30.	 Using	 this	 broth	 agar	 plates	 should	 be	
inoculated	within	15	min	after	adjusting	the	suspension.	
The	 entire	 dried	 agar	 surface	 is	 evenly	 streaked	 in	 the	




selected.	 In	 the	 same	 plate	 positive	 control	 Ketoconazole	 1	
mg/mL	and	negative	 control	DMSO	 is	maintained.	The	plates	






Two	 synthetic	 methods	 for	 the	 preparation	 of	 5‐((2‐(4‐
(1H‐benzoimidazol‐2‐yl)piperidino)quinolin‐3‐yl)methylene)	
thiazolidine‐2,4‐dione	 derivatives	 (3a‐i)	 are	 shown	 in	
Scheme	1.	 Ethyl	 1‐cyclopropyl‐6,7‐difluoro‐8‐methoxy‐4‐oxo‐
1,4‐dihydroquinoline‐3‐carboxylate	(1)	was	reacted	with	boric	












synthesized	 under	 microwave	 irradiation	 technique	 in	 pre‐
sence	 of	 catalytic	 amount	 of	 triethylamine	 adsorbed	 on	
alumina	 solid	 support	 under	 microwave	 irradiation	 and	
surprisingly	 excellent	 yields	 (72‐90%)	 were	 observed.	 The	
melting	point,	FT‐IR,	1H	NMR,	13C	NMR,	Mass	spectral	data	was	





In	 conclusion,	 we	 have	 synthesized	 a	 series	 of	 new	
chemical	 entities	 of	 7‐(4‐(5‐sustituted‐benzo[d]imidazol‐2‐
yl)piperidin‐1‐yl)‐1‐cyclopropyl‐6‐fluoro‐4‐oxo‐1,4‐dihydro	
quinoline‐3‐carboxylic	 acids	 (3a‐i).	 Alternatively,	 the	 same	
compounds	 were	 synthesized	 by	 green	 and	 environmentally	
benign	 methodology	 with	 the	 help	 of	 microwave	 irradiation	
technique.	 All	 the	 compounds	 are	 potentially	 active	 against	
microorganisms.	 It	 is	 evident	 from	 the	 microbial	 screening	
results,	 that	 most	 of	 the	 compounds	 exhibited	 moderate	 to	
good	 activity	 against	 each	 strain	 of	 bacteria	 and	 a	 strain	 of	
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